Carolyn Nancy Krasner, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 31 | 2023 | 4823 | 1.680 |
Why?
|
| Fallopian Tube Neoplasms | 11 | 2020 | 324 | 1.300 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 25 | 2023 | 11472 | 1.070 |
Why?
|
| Peritoneal Neoplasms | 12 | 2021 | 663 | 1.050 |
Why?
|
| Genital Neoplasms, Female | 9 | 2022 | 516 | 0.920 |
Why?
|
| Cyclodextrins | 2 | 2021 | 57 | 0.910 |
Why?
|
| Endometrial Neoplasms | 11 | 2022 | 1351 | 0.750 |
Why?
|
| Camptothecin | 2 | 2021 | 572 | 0.720 |
Why?
|
| Neoplasm Recurrence, Local | 20 | 2023 | 9185 | 0.690 |
Why?
|
| Carboplatin | 16 | 2023 | 799 | 0.670 |
Why?
|
| Tetrahydroisoquinolines | 6 | 2013 | 91 | 0.670 |
Why?
|
| Aromatase Inhibitors | 2 | 2013 | 491 | 0.580 |
Why?
|
| Dioxoles | 5 | 2013 | 104 | 0.560 |
Why?
|
| Doxorubicin | 8 | 2020 | 2215 | 0.550 |
Why?
|
| Ascites | 1 | 2014 | 344 | 0.430 |
Why?
|
| Antibodies, Bispecific | 1 | 2014 | 164 | 0.430 |
Why?
|
| Guanine | 3 | 2009 | 274 | 0.420 |
Why?
|
| Glutamates | 3 | 2009 | 398 | 0.410 |
Why?
|
| Polyethylene Glycols | 4 | 2020 | 1181 | 0.400 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2012 | 692 | 0.400 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2020 | 5163 | 0.390 |
Why?
|
| Paclitaxel | 10 | 2023 | 1707 | 0.380 |
Why?
|
| Infusions, Parenteral | 3 | 2019 | 415 | 0.360 |
Why?
|
| Leiomyosarcoma | 1 | 2013 | 477 | 0.340 |
Why?
|
| Uterine Neoplasms | 2 | 2021 | 1513 | 0.340 |
Why?
|
| Receptors, Progesterone | 1 | 2013 | 1097 | 0.330 |
Why?
|
| Nitriles | 1 | 2013 | 952 | 0.320 |
Why?
|
| Triazoles | 1 | 2013 | 907 | 0.310 |
Why?
|
| Mixed Tumor, Mullerian | 4 | 2009 | 56 | 0.300 |
Why?
|
| Receptors, Estrogen | 2 | 2022 | 2186 | 0.290 |
Why?
|
| Disease-Free Survival | 14 | 2023 | 6891 | 0.290 |
Why?
|
| Drug Administration Schedule | 11 | 2020 | 4929 | 0.280 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2006 | 59 | 0.280 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2009 | 640 | 0.270 |
Why?
|
| Quinazolines | 5 | 2022 | 1355 | 0.260 |
Why?
|
| Infusions, Intravenous | 6 | 2020 | 2271 | 0.250 |
Why?
|
| Cystadenocarcinoma, Serous | 4 | 2021 | 450 | 0.240 |
Why?
|
| Platinum Compounds | 2 | 2016 | 96 | 0.220 |
Why?
|
| Carcinoma, Transitional Cell | 3 | 2016 | 798 | 0.210 |
Why?
|
| Antineoplastic Agents | 6 | 2013 | 13655 | 0.200 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2020 | 623 | 0.190 |
Why?
|
| Neutropenia | 3 | 2023 | 891 | 0.190 |
Why?
|
| DNA Mismatch Repair | 2 | 2022 | 424 | 0.180 |
Why?
|
| Aged | 37 | 2022 | 162944 | 0.170 |
Why?
|
| Female | 55 | 2023 | 379592 | 0.170 |
Why?
|
| Neoplasm Staging | 9 | 2019 | 11001 | 0.170 |
Why?
|
| Middle Aged | 41 | 2021 | 213127 | 0.170 |
Why?
|
| Pyrimidinones | 1 | 2021 | 370 | 0.160 |
Why?
|
| Mullerian Ducts | 1 | 2019 | 198 | 0.160 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2019 | 3471 | 0.150 |
Why?
|
| Vulvar Neoplasms | 2 | 2012 | 272 | 0.150 |
Why?
|
| Neisseriaceae Infections | 1 | 1996 | 5 | 0.150 |
Why?
|
| Erythema Nodosum | 1 | 1996 | 30 | 0.140 |
Why?
|
| Neoplasms, Glandular and Epithelial | 2 | 2012 | 484 | 0.140 |
Why?
|
| Ovariectomy | 1 | 2019 | 660 | 0.140 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2019 | 271 | 0.140 |
Why?
|
| Antibodies, Monoclonal | 4 | 2022 | 9274 | 0.140 |
Why?
|
| Cystadenoma, Serous | 1 | 2016 | 102 | 0.140 |
Why?
|
| Sarcoma | 1 | 2007 | 1895 | 0.130 |
Why?
|
| Adult | 30 | 2021 | 213712 | 0.130 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2003 | 1379 | 0.130 |
Why?
|
| Drug Hypersensitivity | 2 | 2016 | 883 | 0.120 |
Why?
|
| Maximum Tolerated Dose | 3 | 2015 | 891 | 0.120 |
Why?
|
| Humans | 58 | 2023 | 742088 | 0.120 |
Why?
|
| Ribose | 2 | 2023 | 68 | 0.110 |
Why?
|
| Hysterectomy | 1 | 2019 | 927 | 0.110 |
Why?
|
| Lymph Node Excision | 1 | 2019 | 1248 | 0.110 |
Why?
|
| Pyrazoles | 2 | 2021 | 1970 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 2455 | 0.100 |
Why?
|
| Deoxycytidine | 4 | 2015 | 824 | 0.100 |
Why?
|
| Treatment Outcome | 14 | 2023 | 62966 | 0.100 |
Why?
|
| Survival Rate | 4 | 2016 | 12773 | 0.100 |
Why?
|
| Breast Neoplasms | 3 | 2022 | 20774 | 0.100 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 1967 | 0.090 |
Why?
|
| Combined Modality Therapy | 5 | 2009 | 8621 | 0.090 |
Why?
|
| Bacteremia | 1 | 1996 | 962 | 0.090 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 3444 | 0.090 |
Why?
|
| Folic Acid Antagonists | 1 | 2009 | 82 | 0.080 |
Why?
|
| Organoplatinum Compounds | 2 | 2007 | 408 | 0.080 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2013 | 627 | 0.080 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2013 | 2011 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2013 | 6534 | 0.070 |
Why?
|
| Aged, 80 and over | 13 | 2021 | 57683 | 0.070 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2009 | 902 | 0.070 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2009 | 664 | 0.070 |
Why?
|
| Carcinoma, Small Cell | 1 | 2008 | 420 | 0.070 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2006 | 84 | 0.070 |
Why?
|
| Dalteparin | 1 | 2005 | 42 | 0.070 |
Why?
|
| Fallopian Tubes | 1 | 2006 | 182 | 0.070 |
Why?
|
| Ligands | 2 | 2022 | 3293 | 0.060 |
Why?
|
| Octreotide | 1 | 2005 | 145 | 0.060 |
Why?
|
| Exercise | 1 | 2021 | 5611 | 0.060 |
Why?
|
| Desensitization, Immunologic | 1 | 2009 | 483 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2012 | 4029 | 0.060 |
Why?
|
| Telemedicine | 1 | 2021 | 2853 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2012 | 5522 | 0.060 |
Why?
|
| Salvage Therapy | 1 | 2010 | 1269 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 2038 | 0.060 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2005 | 339 | 0.060 |
Why?
|
| Nanoparticles | 1 | 2014 | 1902 | 0.060 |
Why?
|
| Hormones | 1 | 2007 | 884 | 0.060 |
Why?
|
| Leukapheresis | 1 | 2003 | 131 | 0.050 |
Why?
|
| Prognosis | 5 | 2016 | 29010 | 0.050 |
Why?
|
| Diphosphates | 1 | 2022 | 88 | 0.050 |
Why?
|
| Sterilization | 1 | 2003 | 134 | 0.050 |
Why?
|
| Intestinal Obstruction | 1 | 2005 | 424 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2020 | 10943 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2023 | 441 | 0.050 |
Why?
|
| Taxoids | 1 | 2004 | 665 | 0.050 |
Why?
|
| Yttrium Radioisotopes | 1 | 2001 | 93 | 0.050 |
Why?
|
| Follow-Up Studies | 4 | 2016 | 39004 | 0.050 |
Why?
|
| Phthalazines | 1 | 2022 | 361 | 0.040 |
Why?
|
| Boston | 2 | 2010 | 9305 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2022 | 2938 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 12344 | 0.040 |
Why?
|
| Time Factors | 5 | 2016 | 40054 | 0.040 |
Why?
|
| Urinary Catheterization | 1 | 1999 | 201 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 12958 | 0.040 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 1999 | 224 | 0.040 |
Why?
|
| Carcinoma | 1 | 2009 | 2374 | 0.040 |
Why?
|
| Nomograms | 1 | 2019 | 224 | 0.040 |
Why?
|
| Survivors | 1 | 2007 | 2286 | 0.040 |
Why?
|
| Genes, BRCA1 | 1 | 2021 | 780 | 0.040 |
Why?
|
| Aminopterin | 1 | 2016 | 15 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2007 | 2575 | 0.040 |
Why?
|
| Remission Induction | 2 | 2016 | 2384 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 13921 | 0.030 |
Why?
|
| Injections, Subcutaneous | 2 | 2009 | 664 | 0.030 |
Why?
|
| Endometrium | 1 | 2019 | 424 | 0.030 |
Why?
|
| Palatine Tonsil | 1 | 1996 | 193 | 0.030 |
Why?
|
| Carcinosarcoma | 1 | 2016 | 108 | 0.030 |
Why?
|
| Recurrence | 2 | 2023 | 8333 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2005 | 1237 | 0.030 |
Why?
|
| Quality of Life | 2 | 2014 | 12730 | 0.030 |
Why?
|
| Topotecan | 2 | 2006 | 138 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2003 | 1449 | 0.030 |
Why?
|
| Sirolimus | 1 | 2022 | 1562 | 0.030 |
Why?
|
| Prospective Studies | 4 | 2013 | 53187 | 0.030 |
Why?
|
| Neoplasms | 1 | 2022 | 21596 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2019 | 1769 | 0.030 |
Why?
|
| Cisplatin | 2 | 2012 | 1637 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2013 | 2906 | 0.030 |
Why?
|
| Pathology, Molecular | 1 | 2016 | 325 | 0.030 |
Why?
|
| Receptor, erbB-2 | 1 | 2022 | 2410 | 0.030 |
Why?
|
| Survival Analysis | 3 | 2012 | 10248 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2022 | 2107 | 0.030 |
Why?
|
| Young Adult | 1 | 2019 | 56350 | 0.030 |
Why?
|
| Pulmonary Embolism | 1 | 2005 | 2370 | 0.030 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 495 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2021 | 8297 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2016 | 2335 | 0.030 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2013 | 221 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 890 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 2012 | 424 | 0.030 |
Why?
|
| Motivation | 1 | 2021 | 1968 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2021 | 5062 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2014 | 1791 | 0.020 |
Why?
|
| Pain | 1 | 2005 | 4961 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2003 | 3381 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2013 | 627 | 0.020 |
Why?
|
| Registries | 1 | 2006 | 8077 | 0.020 |
Why?
|
| Leukopenia | 1 | 2010 | 208 | 0.020 |
Why?
|
| Vomiting | 1 | 2013 | 632 | 0.020 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2013 | 505 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2014 | 2715 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 3612 | 0.020 |
Why?
|
| Disease Progression | 2 | 2020 | 13256 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2005 | 6347 | 0.020 |
Why?
|
| Adolescent | 4 | 2009 | 85649 | 0.020 |
Why?
|
| Stomatitis | 1 | 2010 | 269 | 0.020 |
Why?
|
| Kidney | 1 | 2023 | 7167 | 0.020 |
Why?
|
| CA-125 Antigen | 1 | 2009 | 279 | 0.020 |
Why?
|
| Age Factors | 2 | 2019 | 18355 | 0.020 |
Why?
|
| Skin Tests | 1 | 2009 | 612 | 0.020 |
Why?
|
| Bleomycin | 1 | 2008 | 499 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2014 | 3557 | 0.020 |
Why?
|
| Etoposide | 1 | 2008 | 637 | 0.020 |
Why?
|
| Vinblastine | 1 | 2008 | 490 | 0.020 |
Why?
|
| Cohort Studies | 3 | 2019 | 40450 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 2007 | 8829 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2001 | 7901 | 0.020 |
Why?
|
| Animals | 3 | 2014 | 168561 | 0.020 |
Why?
|
| Fatigue | 1 | 2013 | 1526 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 9941 | 0.010 |
Why?
|
| Incidence | 2 | 2016 | 20928 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2006 | 647 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2009 | 2615 | 0.010 |
Why?
|
| Thalidomide | 1 | 2008 | 888 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 20086 | 0.010 |
Why?
|
| Benzamides | 1 | 2008 | 1378 | 0.010 |
Why?
|
| Retrospective Studies | 4 | 2016 | 77098 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2008 | 2236 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2009 | 3913 | 0.010 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2005 | 336 | 0.010 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2003 | 272 | 0.010 |
Why?
|
| Gastrointestinal Agents | 1 | 2005 | 494 | 0.010 |
Why?
|
| Blood Cells | 1 | 2003 | 309 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2005 | 2295 | 0.010 |
Why?
|
| Probability | 1 | 2005 | 2502 | 0.010 |
Why?
|
| United States | 3 | 2016 | 69693 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 2900 | 0.010 |
Why?
|
| Sulfonamides | 1 | 2008 | 1932 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2003 | 2123 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2013 | 4249 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2007 | 6452 | 0.010 |
Why?
|
| Piperazines | 1 | 2008 | 2488 | 0.010 |
Why?
|
| Perioperative Care | 1 | 2005 | 997 | 0.010 |
Why?
|
| Catheterization | 1 | 2003 | 1468 | 0.010 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2005 | 1509 | 0.010 |
Why?
|
| Risk | 1 | 2009 | 9679 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2008 | 3465 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 12242 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2008 | 2933 | 0.010 |
Why?
|
| Risk Assessment | 2 | 2009 | 23320 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2003 | 1670 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2007 | 7770 | 0.010 |
Why?
|
| Mutation | 1 | 2016 | 29717 | 0.010 |
Why?
|
| Palliative Care | 1 | 2005 | 3478 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2005 | 15530 | 0.000 |
Why?
|
| Mice | 1 | 2014 | 81045 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 1999 | 15244 | 0.000 |
Why?
|
| Male | 2 | 2003 | 349538 | 0.000 |
Why?
|